Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $13.9B | $14.6B | $15.7B | $18.6B | $20.4B | $21.8B | $23.1B | $24.3B | $22.6B | $23.1B | $19.6B | $20.0B | $21.2B | $22.9B | $21.5B | $22.3B | $24.5B | $28.3B | $28.5B | $34.1B |
Discover the top 20 best undervalued stocks to buy for Nov 2024, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Nov 2024, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Nov 2024.
As of today, Eli Lilly and Company's last 12-month Revenue is $40.9B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Eli Lilly and Company's Revenue growth was 27.4%. The average annual Revenue growth rates for Eli Lilly and Company have been 17.0% over the past three years, 12.5% over the past five years.
Over the last year, Eli Lilly and Company's Revenue growth was 27.4%, which is higher than industry growth of 0.1%. It indicates that Eli Lilly and Company's Revenue growth is Good.